EPO in cancer anemia: Benefits and potential risks

Critical Reviews in Oncology/Hematology

Volumn 62, Issue 2, 2007, Pages 119-125

  Milano, Morgan ^a   Schneider, Maurice ^b  

^a Centre Hospitalier Universitaire de Nice   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Anaemia; Cancer; Erythropoietin

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL TRIAL; CYTOTOXICITY; HUMAN; INCIDENCE; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW;

ANEMIA; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ERYTHROPOIETIN; HEMOGLOBINS; HUMANS; NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY; RISK FACTORS;

EID: 34147095475     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.11.011     Document Type: Review

References (72)

1. Yellen S.B., Cella D.F., Webster K., Blendowski C., and Kaplan E. Measuring fatigue and other anemia-related symptoms with the functionnal assessment of cancer therapy (FACT) measurement system. J Pain Symptom 13 (1997) 63-74
2. Glaspy J., Bukowski R., Steinberg D., Taylor C., Tchekmedyian S., and Vadhan-Raj S. Impact of therapy with epoietin alfa on clinical outcomes in patients with non myeloid malignancies during cancer chemotherapy in a community oncology practice. J Clin Oncol 15 (1998) 1218-1234
3. Gregory N. Attaining target hemoglobin levels in patients new to dialysis: individualizing therapy based on initial hemoglobin levels. Nephrol Nurs J 31 (2004) 672-675
4. Littlewood T.J. Effects of epoietin alfa on hematologic parameters and QOL in cancer patients receiving non-platinum chemotherapy: result of randomized double blind placebo controlled trial. J Clin Oncol 19 (2001) 2865-2874
5. Bron D., Meuleman N., and Mascaux C. Biological basis of anemia. Semin Oncol 28 (2001) 1-6
6. Skillings J.R., Sridhar F.G., Wong C., and Paddock L. The frequency of red cell transfusion for anemia in patients receiving chemotherapy. Am J Clin Oncol 16 (1993) 22-25
7. Skillings J.R., Rogers-Melamed I., Nabholtz J.M., et al. An epidemiological review of red cell transfusions in cancer chemotherapy. Cancer Prev Control 3 (1993) 207-212
8. Barett-Lee P.J., Bailey N.P., O'Brien M.E.R., and Wager E. Large scale UK audit of blood transfusion requirements and anemia in patients receiving cytotoxic chemotherapy. Br J Cancer 82 (2000) 93-97
9. Coiffier B., Guastalla J.P., Pujade-Lauraine E., et al. Predicting cancer-associated anemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer 37 (2001) 1617-1623
10. Knigh K., Wase S., and Balducci L. Prevalence and outcomes of anemia in cancer. Am J Med 116 7A (2004) 11S-26S
11. Ludwig H., Van Belle S., Barrett-Lee P., et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40 (2004) 2293-2306
12. Curt G.A. The impact of fatigue on patients with cancer: overview of FATIGUE 1 and 2. Oncologist 5 Suppl. 2 (2000) 9-12
13. Vogelzang N.J., Breitbart W., Cella D., et al. Patient, caregiver and oncologist perceptions of cancer-related fatigue: result of a tripart assessment survey by the fatigue coalition. Semin Hematol 34 3 Suppl. 2 (1997) 4-12
14. Manegold C. The cause and prognostic significance of low hemoglobin levels in tumor patients. Strahlenther Onkol 174 Suppl. IV (1998) 17-19
15. Caro J.J., Salas M., Ward A., and Goss G. Anemia as an independant prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91 (2001) 2214-2221
16. Van Belle S.J., and Cocquyt V. Impact of hemoglobin levels on the outcome of cancer treated with chemotherapy. Crit Rev Oncol hematol 47 (2003) 1-11
17. Grant D.G., Hussain A., and Hurman D. Pretreatment anemia alters outcome in early squamous cell carcinoma of the larynx treated by radical radiotherapy. J Laryngol Otol 113 (1999) 829-833
18. Grogan M., Thomas J.M., Melamed I., et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86 (1999) 1528-1536
19. Wigren T., Oksanen H., and Kellokumpu-Lethinen P. A practical prognostic index for inoperable non small cell lung cancer. J Cancer Res Clin Oncol 123 (1997) 259-266
20. Phan T., Crane C., Mendoza T., et al. Low hemoglobin levels after preoperative chemotherapy for locally advance rectal cancer are associated with a worse survival. Proc Am Soc Clin Oncol 20 (2001) (abst 596)
21. Shasha D. The negative impact of anemia on radiotherapy and chemo-radiation outcomes. Semin Oncol 38 (2001) 8-15
22. Hockel M., and Vaupel P. Tumor hypoxia: definitions and current clinical biological and molecular aspects. J Natl Cancer Inst 93 (2001) 266-276
23. Fyles A.W. Oxygenation predicts radiation response and survival in patients wuith cervix cancer. Radiother Oncol 48 (1998) 149-156
24. Nordsmark M., and Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 57 (2000) 39-43
25. Brizel D.M. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56 (1996) 941-943
26. Vaupel P., Thews O., and Hockel M. Treatment resistance of solid tumors. Med Oncol 18 (2001) 243-259
27. Nowrousian M.R. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anemia in patients with solid tumors. Med Oncol 15 Suppl. 1 (1998) S19-S28
28. Spivak J.L. Anemia and erythropoiesis in cancer. Adv Stud Med 2 (2002) 212-219
29. Spivak J.L. The biology and clinical applications of recombinant erythropoietin. Semin Oncol 25 Suppl. 7 (1998) 7-11
30. Mulcahy J.L. The erythropoietin receptor. Semin Oncol 28 Suppl. 8 (2001) 19-23
31. Abels R.J. Blood transfusions in cancer patients. Semin Oncol 19 32 Suppl. 8 (1992) 29-35
32. Walker R.H. Special report: transfusion risks. Am J Clin Pathol 88 (1987) 374-378
33. Mercadante S., Gebbia V., Marrazzo A., and Filosto S. Anemia in cancer: patho-physiology and treatment. Cancer Treat Rev 26 (2000) 303-311
34. Winearls C.G., Oliver D.O., Pippard M.J., Reid C., Downing M.R., and Cotes P.M. Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic haemodialysis. Lancet 11 (1986) 1175-1177
35. Bohlius J.F., Wilson J., Seidenfeld J., and Piper M. Recombinant human erythropoietins and cancer patients: updates meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98 (2006) 708-714
36. Gabrilove J.L., Cleeland C.S., Livingston R.B., Sarokhan B., Winer E., and Einhorn L.H. Clinical evaluation of once-weekly dosing of epoietin alpha in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 191 (2001) 2875-2882
37. Beris P. EPO: gene, molecule and receptor. In: Bokemeyer C., and Ludwig H. (Eds). Anemia in cancer vol. 19 (2001), Elsevier Oxford 105-113 ESO scientific updates, vol. 6
38. Hedenus M., Hansen S., Taylor K., et al. Randomized dose-finding study of darbepoietin a in anemic patients with lymphoproliferative malignancies. Br J Haematol 119 (2002) 79-86
39. Erbayraktar S., Ylmaz O., Gokmen N., and Brines M. Erythropoietin is a multifunctional tissue-protective cytokine. Curr Haematol 2 (2003) 465-470
40. Cella D., Dobrez D., and Galsby J. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 14 (2003) 511-519
41. Abels R. Erythropoietin for anemia in cancer patients. Eur J Cancer 29A Suppl 2 (1993) S2-S8
42. Case Jr. D.C., Bukowsi R.M., Carey R.W., et al. Recombinant human erythropoietin therapy for anemic cancer patients. J Natl Cancer Inst 85 (1993) 801-806
43. Seidenfeld J., Piper M., Flamm C., et al. Epoietin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93 (2001) 1204-1214
44. Welch R.S., James R.D., and Wikinson P.M. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer. Cancer J Sci Am 1 (1995) 261
45. Auerbach M., Ballard H., Trout J.R., et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22 (2004) 1301-1307
46. Demetri G.D., Kris M., Wade J., Degos L., and Cella D. Quality of life benefit in chemotherapy patients treated with epoietin a is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 16 (1998) 3412-3425
47. Ludwig H., Sundal E., Pecherstorfer M., et al. Recombinant human erythropoietin for the correction of cancer-related anemia with and without concomitant cytotoxic chemotherapy. Cancer 76 (1995) 2319-2329
48. Bokemeyer C., Aapro M.S., Courdi A., et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40 (2004) 2201-2216
49. Razzouk B.I., Hord J.D., Hockenberry M., et al. Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. J Clin Oncol 22 (2006) 3583-3589
50. Cleeland C.S., Demetri G.D., Glaspy J., et al. Identifying hemoglobin level for optimal quality of life: results of an incremental analysis (abstract). Proc Am Soc Clin Oncol 18 (1999) (547a): abst 2215
51. Osterborg A. Randomized, double blind, placebo-controlled trial of recombinant human erythropoietin, epoietin beta, in hematologic malignancies. J Clin Oncol 20 (2002) 2486-2494
52. Ross S.D., Allen I.E., Henry D.H., et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 28 (2006) 801-831
53. Farrell F., and Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. The Oncologist 9 (2004) 18-30
54. Arcasoy M.O., Amin K., Karayal A.F., et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 82 (2002) 911-918
55. Kumar S.M., Acs G., Fang D., Herlyn M., Elder D.E., and Xu X. Functional erythropoietin autocrine loop in melanoma. Am J Pathol 166 (2005) 823-830
56. Dagnon K., Pacary E., Commo F., et al. Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. Clin Cancer Res 11 (2005) 993-999
57. McBroom J.W., Acs G., Rose G.S., et al. Erythropoietin receptor function and expression in epithelial ovarian carcinoma. Gynecol Oncol (2005)
58. Lai S.Y., Childs E.E., Xi S., et al. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 24 (2005) 4442-4449
59. Yasuda Y., Fujita Y., Matsuo T., et al. Erythropoietin regulates tumor growth of human malignancies. Carcinogenesis 24 (2003) 1021-1029
60. LaMontagne K.R., Butler J., Marshall D.J., et al. Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 5 (2006) 347-355
61. Mittelman M., Neumann D., Peled A., Kanter P., and Haran-Ghera N. Erythropoietin induces tumor regression and anti-tumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 5 (2001) 5181-5186
62. Carvalho G., Lefaucheur C., Cherbonnier C., et al. Chemosensitization by erythropoietin through inhibition of the NF-kB rescue pathway. Oncogene 24 (2005) 737-745
63. Glaser C.M., Millesi W., Komek G.V., et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemo-radiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50 (2001) 705-715
64. Pangalis G.A., Siakantaris M.P., and Angelopoulou M.K. Downstaging Rai stage IIIB chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin. Haematologica 87 (2002) 500-506
65. Rades D., Tribus S., Yekebas E., et al. Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: final results of a prospective observational. Int J Radiat Oncol Biol Phys 65 (2006) 459-465
66. Leyland Jones B., Semiglazov V., Pawlicki M., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23 (2005) 5960-5972
67. Henke M., Laszig R., Rübe C., et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomised, double blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
68. Henke M., Mattern D., Pepe M., et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J Clin Oncol 24 (2006) 4708-4713
69. Rizzo D., Lichtin A.E., Woolf S.H., et al. Use of epoietin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology ant the American Society of Hematology. J Clin Oncol 20 (2002) 4083-4107
70. Spaeth D., Casadevall N., Daouphars M., et al. Summary version of the Standards, Options and Recommandations for the use of recombinant erythropoietin in the management of anemia in oncology. Bull Cancer 91 2 (2004) 179-188
71. Becker A., Stadler P., Lavey R.S., et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 46 (2000) 459-466
72. Casadevall N., Durieux P., Dubois S., et al. Health, economic and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndro: a randomized, controlled trial. Blood 104 (2004) 321-327